Research Overview: Zyrik
Zyrik 300mg represents a pharmaceutical-grade allopurinol preparation manufactured by Cipla for in-vitro research applications. Allopurinol is a xanthine oxidase inhibitor that researchers examine for its effects on purine metabolism and uric acid production pathways. Laboratory studies investigate this compound’s mechanism of action in cellular models, where it functions as a competitive inhibitor of xanthine oxidase, the enzyme responsible for converting hypoxanthine to xanthine and xanthine to uric acid. Research scientists at Stroid UK Shop utilise this preparation to evaluate metabolic enzyme inhibition in controlled laboratory environments.
Laboratory Applications
Research applications for Zyrik focus on studying purine metabolism disruption and cellular response to xanthine oxidase inhibition. Scientists analyse this compound in models investigating hyperuricemia conditions, where researchers evaluate the biochemical pathways affected by allopurinol treatment. Laboratory studies examine the compound’s effects on cellular ATP production, as xanthine oxidase inhibition can influence energy metabolism in various cell types. Research teams investigating inflammatory pathways often study allopurinol alongside selective androgen receptor modulators to understand metabolic interactions. Additionally, researchers examine this compound in oxidative stress models, as xanthine oxidase produces reactive oxygen species during normal enzymatic activity. Studies involving peptide research compounds may incorporate allopurinol to investigate combined metabolic effects.
Specifications
| Parameter | Value |
|---|---|
| Active Ingredient | Allopurinol |
| Strength | 300mg per tablet |
| Manufacturer | Cipla Pharmaceuticals |
| CAS Number | 315-30-0 |
| Molecular Formula | C₅H₄N₄O |
| Molecular Weight | 136.11 g/mol |
| Storage | Room temperature, dry environment |
Researchers examining allopurinol and related compounds appreciate the consistent formulation quality that Cipla provides for laboratory investigations.
Research Compliance
Zyrik 300mg Cipla tablets are supplied exclusively for in-vitro laboratory research purposes. This product is not intended for human consumption, therapeutic use, or any application outside controlled research environments. Research institutions must ensure proper handling protocols and maintain appropriate documentation for all laboratory studies involving this compound.
